Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker…
Novo Holdings completes $16.5 billion takeover of Catalent By Reuters Novo Holdings completes $16.5 billion takeover of Catalent…
Novo Holdings completes $16.5 bln takeover of Catalent Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after…
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s…
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global…
Novo Holdings $16.5 billion Catalent buy wins EU antitrust approval By Reuters Novo Holdings $16.5 billion Catalent buy wins EU antitrust approval…
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal By Reuters EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal…
Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings By Reuters Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings…
Catalent reports Q1 loss, misses market expectations By Investing.com Catalent reports Q1 loss, misses market expectations…
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the…
Roche comes out against clearing takeover of drug manufacturer Catalent By Reuters Roche comes out against clearing takeover of drug manufacturer Catalent…
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings buyout By Reuters Catalent CEO to remain in charge of contract drugmaker after Novo Holdings buyout…
Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent Ardena acquires Catalents Somerset, NJ facility, expanding its US presence and boosting advanced oral drug product manufacturing capabilities.…
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent By Reuters Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent…
Catalent (CTLT) Expands Its Facility Capabilities in Germany Catalents (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical…
Global Dermal Toxicity Testing Market Size To Exceed USD 4.95 Billion By 2033 | CAGR of 8.11% The Global Dermal Toxicity Testing Market Size was Valued at USD 2.27 Billion in 2023 and the Worldwide Dermal Toxicity…
Catalent exec sells over $76k in company stock By Investing.com Catalent exec sells over $76k in company stock…
Catalents (CTLT) Latest Partnership to Boost Clinical Trials Catalents (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving…
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.…
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings Robbins LLP is investigating the acquisition of Catalent, Inc. (CTLT) by Novo Holdings to determine if it is in the…
Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal Ares Management Corp. and Blue Owl Capital Inc. are leading a group of private credit lenders providing $4.8 billion of…
Catalent executive sells $21,749 in company stock By Investing.com Catalent executive sells $21,749 in company stock…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…